Literature DB >> 7810298

Gerstmann-Sträussler-Scheinker disease showing beta-protein type cerebellar and cerebral amyloid angiopathy.

S I Ikeda1, N Yanagisawa, D Allsop, G G Glenner.   

Abstract

Cerebral amyloid angiopathy is observed in several brain degenerative disorders, but this pathological condition has received little attention in Gerstmann-Sträussler-Scheinker disease (GSS). We report a 69-year-old man who showed the cardinal features of GSS together with typical and extensive congophilic angiopathy. Immunohistochemical studies revealed that the vast majority of the amyloid plaques present in the brain of this patient were consistently labeled by anti-prion protein (PrP) antibody. Double immunostaining disclosed many additional beta-protein immunoreactive plaque-like lesions, including a special type of "hybrid" plaque with colocalization of PrP and beta-protein (beta-PrP). The vascular amyloid deposits seen in both the cerebellum and cerebrum were immunoreactive only to anti-beta-protein antibody. It seems likely that the extensive deposition of beta-protein amyloid (including brain vascular amyloidosis) seen in this and other similar cases is part of pathology of GSS, although the possibility that this finding is due to ageing or concomitant Alzheimer's disease cannot be completely ruled out.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7810298     DOI: 10.1007/bf00293403

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  31 in total

1.  Early senile plaques in Alzheimer's disease demonstrated by histochemistry, immunocytochemistry, and electron microscopy.

Authors:  S Ikeda; N Yanagisawa; D Allsop; G G Glenner
Journal:  Hum Pathol       Date:  1990-12       Impact factor: 3.466

2.  CNS amyloid proteins in neurodegenerative diseases.

Authors:  G W Roberts; R Lofthouse; D Allsop; M Landon; M Kidd; S B Prusiner; T J Crow
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

3.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

4.  A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

Authors:  L Davies; B Wolska; C Hilbich; G Multhaup; R Martins; G Simms; K Beyreuther; C L Masters
Journal:  Neurology       Date:  1988-11       Impact factor: 9.910

5.  A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining.

Authors:  H Yamaguchi; S Hirai; M Morimatsu; M Shoji; Y Ihara
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

6.  Beta PP participates in PrP-amyloid plaques of Gerstmann-Sträussler-Scheinker disease, Indiana kindred.

Authors:  O Bugiani; G Giaccone; L Verga; B Pollo; B Frangione; M R Farlow; F Tagliavini; B Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  1993-01       Impact factor: 3.685

7.  Colocalization of prion protein and beta protein in the same amyloid plaques in patients with Gerstmann-Sträussler syndrome.

Authors:  M Miyazono; T Kitamoto; T Iwaki; J Tateishi
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

8.  Gerstmann-Sträussler syndrome--a variant type: amyloid plaques and Alzheimer's neurofibrillary tangles in cerebral cortex.

Authors:  N Amano; S Yagishita; S Yokoi; Y Itoh; J Kinoshita; T Mizutani; T Matsuishi
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

9.  Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene.

Authors:  S R Dlouhy; K Hsiao; M R Farlow; T Foroud; P M Conneally; P Johnson; S B Prusiner; M E Hodes; B Ghetti
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

10.  Polysialosyl glycoconjugates defined by monoclonal antibody M6704 are expressed in human gliomas and embryonic neurons.

Authors:  J Nakayama; T Katsuyama; E Sugiyama; Y Hirabayashi
Journal:  J Histochem Cytochem       Date:  1993-10       Impact factor: 2.479

View more
  5 in total

1.  Transthyretin-related familial amyloid polyneuropathy: evaluation of CSF enhancement on serial T1-weighted and fluid-attenuated inversion recovery images following intravenous contrast administration.

Authors:  Toshinori Hirai; Yukio Ando; Masayuki Yamura; Mika Kitajima; Yoshiko Hayashida; Yukunori Korogi; Taro Yamashita; Yasuyuki Yamashita
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP.

Authors:  Casper Jansen; Piero Parchi; Sabina Capellari; Ad J Vermeij; Patrizia Corrado; Frank Baas; Rosaria Strammiello; Willem A van Gool; John C van Swieten; Annemieke J M Rozemuller
Journal:  Acta Neuropathol       Date:  2009-11-13       Impact factor: 17.088

3.  Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK.

Authors:  Diane L Ritchie; Peter Adlard; Alexander H Peden; Suzanne Lowrie; Margaret Le Grice; Kimberley Burns; Rosemary J Jackson; Helen Yull; Michael J Keogh; Wei Wei; Patrick F Chinnery; Mark W Head; James W Ironside
Journal:  Acta Neuropathol       Date:  2017-03-27       Impact factor: 17.088

Review 4.  Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases?

Authors:  Diane L Ritchie; Marcelo A Barria
Journal:  Biomolecules       Date:  2021-02-02

5.  Extracellular Prion Protein Aggregates in Nine Gerstmann-Sträussler-Scheinker Syndrome Subjects with Mutation P102L: A Micromorphological Study and Comparison with Literature Data.

Authors:  Nikol Jankovska; Radoslav Matej; Tomas Olejar
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.